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Abstract
Introduction: Mesenchymal stem cells (MSCs) have been identified as a viable treatment for inflammatory bowel
disease (IBD). MSCs derived from bone marrow (BM-MSCs) have predominated in experimental models whereas the
majority of clinical trials have used MSCs derived from adipose tissue (AT-MSCs), thus there is little consensus on the
optimal tissue source. The therapeutic efficacies of these MSCs are yet to be compared in context of the underlying
dysfunction of the enteric nervous system innervating the gastrointestinal tract concomitant with IBD. This study aims to
characterise the in vitro properties of MSCs and compare their in vivo therapeutic potential for the treatment of enteric
neuropathy associated with intestinal inflammation.
Methods: BM-MSCs and AT-MSCs were validated and characterised in vitro. In in vivo experiments, guinea-pigs received
either 2,4,6-trinitrobenzene-sulfonate acid (TNBS) for the induction of colitis or sham treatment by enema. MSCs were
administered at a dose of 1x106 cells via enema 3 hours after the induction of colitis. Colon tissues were collected 24
and 72 hours after TNBS administration to assess the level of inflammation and damage to the ENS. MSC migration to
the myenteric plexus in vivo was elucidated by immunohistochemistry and in vitro using a modified Boyden
chamber assay.
Results: Cells exhibited multipotency and a typical surface immunophenotype for validation as bona fide MSCs.
In vitro characterisation revealed distinct differences in growth kinetics, clonogenicity and cell morphology between
MSC types. In vivo, BM-MSCs were comparatively more effective than AT-MSCs in attenuating leukocyte infiltration and
neuronal loss in the myenteric plexus. MSCs from both sources equally ameliorated body weight loss, gross
morphological damage to the colon, changes in the neurochemical coding of neuronal subpopulations and the
reduction in density of extrinsic and intrinsic nerve fibres innervating the colon. MSCs from both sources
migrated to the myenteric plexus in in vivo colitis and in an in vitro assay.
Conclusions: These data from in vitro experiments suggest that AT-MSCs are ideal for cellular expansion.
However, BM-MSCs were more therapeutic in the treatment of enteric neuropathy and plexitis. These
characteristics should be considered when deciding on the MSC tissue source.
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Introduction
Mesenchymal stem cells (MSCs) otherwise known as
multipotent stromal cells have been proposed as a
potential treatment option for chronic inflammation and
neurological damage [1]. These cells are identified by
their multipotency as implied by the name [2]; however
it is the numerous other characteristics that attract
investigations into their therapeutic potential. MSCs are
readily isolated from adult bone marrow or adipose
tissue [3–5]. In vitro, MSCs are easily purified due to
their adherence to plastic and proliferation, generating
high yields of cells for treatments [6]. The immune eva-
sive nature of MSCs may also be exploited for allogeneic
and, if required, xenogeneic transplantation [7, 8]. Once
administered, MSCs migrate towards sites of inflamma-
tion by chemotaxis [9]. Engrafted MSCs can then exert
immunomodulatory activities and promote endogen-
ous repair mechanisms through secretion of cytokines
in addition to angiogenic and trophic factors [10–13].
These traits make MSCs ideal candidates to target both
the inflammatory pathology and structural damage to
the intestines of inflammatory bowel disease (IBD)
patients.
Current treatments for IBD often fail to maintain pe-
riods of remission effectively throughout the prolonged
course of illness due to their inefficacy or toxicity [14],
thus necessitating the development of novel treatments.
Clinical trials of MSC application in IBD have recog-
nised their therapeutic efficacy, feasibility and safety.
Specifically, MSCs have shown promise in the treatment
of the fistulising and inflammatory luminal pathologies
of Crohn’s disease [15, 16]. Despite the recruitment of
patients who are refractory to conventional therapy,
Forbes et al. [17] demonstrated clinical remission and
endoscopic improvement in more than half of patients
with Crohn’s colitis and ileocolitis. However, further
studies are crucial to optimise MSC therapy for better
treatment outcomes.
Investigating the facets of MSCs derived from different
tissue sources may provide an opportunity to improve
therapy. In experimental models and clinical trials,
MSCs from either bone marrow or adipose tissue have
been used. MSCs derived from bone marrow (BM-
MSCs) have predominated in experimental models,
whereas the majority of clinical trials have used MSCs
derived from adipose tissue (AT-MSCs) [18], thus there
is little consensus on the optimal tissue source of MSCs.
The favoured use of AT-MSCs in the clinic is presum-
ably owing to the availability and less invasiveness of
obtaining adipose tissue [19]. Furthermore, the cell yield
of AT-MSCs is predicted to be 500 fold that of BM-
MSCs [20]. Nonetheless, differences in the functional
efficacy of these MSCs could influence the preference of
tissue source.
Studies directly comparing BM-MSCs and AT-MSCs
are limited. However, MSC application in different in
vivo models of various inflammatory conditions indicate
that BM-MSCs exhibit functionally better immunomod-
ulatory properties [21–24]. Conversely, AT-MSCs have
been reported to be functionally better than BM-MSCs
in ameliorating the clinical and pathological severity of
autoimmune demyelination due to their enhanced ability
to migrate to the central nervous system [25]. In intes-
tinal inflammation, studies have largely investigated
MSC protection of the mucosal integrity and polarisa-
tion of the pro-inflammatory signalling milieu [26–31].
Recently, we have demonstrated that human BM-MSCs
can attenuate neuropathy in the enteric nervous system
(ENS) of guinea-pigs with colitis [32]. Comparisons be-
tween BM-MSCs and AT-MSCs are yet to be elucidated
in the context of inflammation-induced neurological dam-
age concomitant with intestinal inflammation.
The colon is innervated extrinsically by parasympa-
thetic vagus nerve fibres, sympathetic and sensory affer-
ent fibres of the dorsal root ganglion [33]. Intrinsic
innervation is governed by the enteric nervous system
(ENS) which can function independently of extrinsic in-
put and justifies its label as ‘the little brain’ [34]. The
ENS consists of a network of neurons and glial cells
spanning the length of the gastrointestinal tract which
form the ganglia. The ganglia, containing individual
neuronal subpopulations, are localised within the sub-
mucosal plexus regulating secretion and vasodilation,
and the myenteric plexus coordinating muscular con-
traction [35]. Persistent intestinal inflammation associ-
ates with disruption to the ENS causing symptomatic
gut dysfunctions [36–39]. Neuropathy and axonal dam-
age are likely to be consequential of inflammation in the
bowel [40–43]. However, in non-inflamed regions, the
invasion of leukocytes to the level of the enteric plex-
uses, termed plexitis, may be an indicator of inflamma-
tory relapse [44–46]. Furthermore, the neurochemical
coding that defines neuronal subpopulations is altered in
animal models of intestinal inflammation and IBD pa-
tients [41, 47–50]. These changes are not only respon-
sible for the symptoms of IBD but can perpetuate
further intestinal inflammation. Thus, the ENS presents
as a therapeutic target for IBD. In this study we per-
formed a comparison in the in vitro characteristics and
in vivo therapeutic efficacy of BM-MSCs and AT-MSCs
for the treatment of inflammation-induced neurological
changes in the colon.
Methods
Animals
Male and female Hartley guinea-pigs weighing 140–280 g
were received from the South Australian Health and
Medical Research Institute (SAHMRI). All guinea-pigs
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were housed in a temperature-controlled environment
with 12-hour day/night cycles and had ad libitum access
to food and water. The average weight of guinea-pigs that
underwent experimental procedures was 248 ± 5 g. All
procedures were performed under approval of the Victoria
University Animal Experimentation Ethics Committee
(ethics number AEETH 12–012) and conducted according
to the Australian National Health and Medical Research
Council (NHMRC) Code of Practice for the Care and Use
of Animals for Scientific Purposes.
Cell culture and passaging
Pre-established cell lines of human MSCs (Tulane
University, New Orleans, LA, USA) were derived from
the bone marrow and adipose tissue of four donors.
MSCs were cultured to the fourth passage for all subse-
quent experiments and exhibited a viability of minimum
95 % at the time of injection. Cells were plated at an ini-
tial density of 60 cells/cm2 and incubated in expansion
medium (α-MEM supplemented with 100 U/mL penicil-
lin/streptomycin, 1 % glutaMAX (Gibco®, Life Technolo-
gies, Melbourne, Australia) and 16.5 % foetal bovine
serum (FBS; mesenchymal stem cell-qualified, Gibco®)
which was replenished every 48-72 h for 10–14 days
until the cells were 70-85 % confluent (maximum).
MSCs were trypsinised and either reseeded for expan-
sion or collected for in vitro experiments and in vivo
treatment of guinea-pigs. All MSC cultures were incu-
bated at 37 °C in 5 % CO2 throughout the study.
Surface marker expression
MSCs were immunolabelled as previously described [51]
with CD29-Alexa Fluor 488 (clone TS2/16), CD34-
phycoerythrin (PE) (clone 581), CD45-PerCPCy5.5 (clone
H130), CD44-Brilliant Violet 421 (clone IM7), CD73-
Brilliant Violet 421 (clone AD2), and CD90-Alexa Fluor
647 (clone 5E10) (1:100) (Biolegend, San Diego, CA,
USA). Data were acquired on a BD FACSCanto II flow
cytometer with FACSDiva v6.1 software (BD Biosciences,
Sydney, Australia). Unlabelled cells were incubated with
7-aminoactinomycin D (7-AAD) (1:20) (Life Technologies,
Melbourne, Australia) for one min before acquisition to
determine the viability of the cell suspensions.
Differentiation assay
The differentiation potential of MSCs was assessed using
the StemPro® Adipogenesis Differentiation Kit and Stem-
Pro® Osteogenesis Differentiation Kit according to the
manufacturer’s instructions (Life Technologies). To detect
adipogenesis, MSCs were fixed in 10 % neutral buffered
formalin after two weeks in culture and lipid vacuoles were
stained with Oil red O (Sigma-Aldrich, Sydney, Australia)
in 60 % (v/v) isopropanol. Cells were then counterstained
with haematoxylin. To detect osteogenesis, MSCs were
fixed in 10 % neutral buffered formalin after three weeks in
culture and calcium deposits were stained with 2 % (w/v)
Alizarin red S (Sigma-Aldrich) in distilled water.
Colony forming unit-fibroblast (CFU-f) assay
MSCs were seeded in 90 mm size petri dishes at low
density (100 cells/dish). Expansion medium was changed
every three to four days. After two weeks in culture,
MSCs were fixed and stained with 0.5 % (w/v) crystal
violet (Sigma-Aldrich) in methanol for 30 min before
colonies containing >50 cells (CFU-f ) [52] were counted
under a dissection microscope.
MSC growth kinetics and cell morphology
To assess cell proliferation, MSCs were cultured in tripli-
cates and seeded at 60 cells/cm2 in 25 cm2 cell culture
flasks containing 5 mL of expansion medium which was
replaced every 48-72 h. Cells were trypsinised and counted
with a haemocytometer at days 3, 7, and 14. The popula-
tion doubling level (PDL) was calculated using the for-
mula PDL = (log2 [final no. of cells]) - (log2 [initial cells
seeded]) [53]. For morphological studies, MSCs were
seeded at 100 cells/cm2 in six-well plates and analysed
after 48 h. MSCs were morphologically characterised into
one of two categories defined by the presence of elongated
cell bodies with long thin processes (spindle) or flat bodies
with irregular processes (flat).
Induction of colitis and MSC administration
To induce colitis, 2,4,6-trinitrobenzene-sulfonate acid
(TNBS) (Sigma-Aldrich) was dissolved in 30 % ethanol to
a concentration of 30 mg/kg and administered intrarectally
7 cm proximal to the anus (total volume of 300 μL) by a
lubricated silicone catheter [42]. Guinea-pigs were anes-
thetised with isoflurane (1-4 % in O2) during the proced-
ure and held at an inverted angle to prevent leakage.
Sham-treated guinea-pigs underwent the same procedure
without administration of TNBS. Guinea-pigs were treated
with MSCs three hours after TNBS administration at the
peak of tissue damage [54]. MSCs were administered by
enema at a dose of 1x106 cells in 300 μL of sterile PBS.
Guinea-pigs were weighed and monitored daily following
treatment. At 24 or 72 h after TNBS administration, ani-
mals were culled via stunning and exsanguination [55].
Segments of the distal colon were collected for histological
and immunohistochemical studies.
Tissue preparation
Colon tissues were cut along the mesenteric border,
stretched and pinned flat with the mucosal side up for
wholemount preparations. Tissue samples were fixed
overnight at 4 °C in Zamboni’s fixative (2 % formaldehyde
and 0.2 % picric acid) and subsequently washed in di-
methyl sulfoxide (DMSO) (Sigma-Aldrich) (3x10min) and
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PBS (3x10min) to remove fixative. Samples for histology
were fixed in 10 % buffered formalin solution and stored
in 70 % ethanol until embedding.
Immunohistochemistry
Immunohistochemistry was performed on wholemount
preparations of the longitudinal muscle and myenteric
plexus (LMMP). The preparations were dissected by re-
moving the mucosa, submucosa and circular muscle
layers to expose the myenteric plexus. LMMPs were in-
cubated in 10 % normal donkey serum (NDS; Merck
Millipore, Melbourne, Australia) at room temperature
for one hour before immunolabelling. For neuronal
counting, LMMPs were incubated overnight at 4 °C with
primary antibodies: anti-Hu (mouse, clone 15A7.1,
1:500; Merck Millipore), anti-neuronal nitric oxide syn-
thase (nNOS) (goat, 1:500; Novus Biologicals, Littleton,
CO, USA), anti-choline acetyltransferase (ChAT) (goat,
1:500; Merck Millipore), anti-CD45 (mouse, clone IH-1,
1:200; Abcam, Melbourne, Australia) and anti-protein
gene product 9.5 (PGP9.5) (rabbit, 1:500; Abcam). For
analysis of immunoreactive (IR) area density, LMMP tis-
sues were incubated with primary antibodies: anti-
calcitonin gene-related peptide (CGRP) (rabbit, 1:3000;
Sigma), anti-tyrosine hydroxylase (TH) (sheep, 1:1000;
Merck Millipore) and anti-vesicular acetylcholine trans-
porter (VAChT) (goat, 1:500; Merck Millipore). Tissues
were washed (3x10 min PBS) and incubated for two h at
room temperature with secondary antibodies: donkey anti-
mouse Alexa Fluor 594 (1:200), donkey anti-goat fluores-
cein isothiocyanate (FITC) 488 (1:200), donkey anti-mouse
FITC 488 (1:200) and donkey anti-rabbit Alexa Fluor 594
(1:200), donkey anti-sheep FITC 488 (1:200) and donkey
anti-goat Alexa Fluor 647 (1:200) (all from Jackson Immu-
noresearch, West Grove, PA, USA). After washing, tissues
were mounted on glass slides with fluorescent mounting
medium (Dako North America, Inc., Carpinteria, CA,
USA). For cross sections, tissues were frozen in optimal
cutting temperature compound (Tissue Tek-Sakura, Tokyo,
Japan) and sections were cut at a thickness of 20 μm.
Cross-sections were labelled with rabbit anti-α-actin
(1:1000; Abcam) followed by donkey anti-rabbit Alexa
Fluor 594 (1:200) and FITC conjugated anti-human
leukocyte antigen (HLA)-A,B,C (1:50; BioLegend).
Histology
Tissues were embedded in paraffin and cut into 5 μm
sections which were then deparaffinised, cleared, and
rehydrated in graded ethanol. Cross sections of the
colon were stained with haematoxylin and eosin and
mounted on glass slides with distrene plasticizer xylene
(DPX) mountant. Gross morphological damage in cross
sections of the distal colon was assessed by histological
grading of four parameters: mucosal flattening (0 = normal,
3 = severe flattening), occurrence of haemorrhagic sites
(0 = none, 3 = frequent sites), loss of goblet cells (0 =
normal, 3 = severe loss of cells), and variation of the cir-
cular muscle (0 = normal, 3 = considerable thickening of
muscular layer) [32, 56].
Imaging
Confocal microscopy was performed using an Eclipse Ti
confocal laser scanning system (Nikon, Tokyo, Japan).
Fluorophores were visualised using a 488 nm excitation
filter for Alexa 488 or FITC and a 559 nm excitation fil-
ter for Alexa 594. Z-series images were acquired at a
nominal thickness of 0.5 μm (512x512 pixels). The num-
ber of myenteric neurons Hu-IR, nNOS-IR, and ChAT-
IR, as well as CD45-IR cells were counted within eight
randomly captured images (total area size 2 mm2) per
preparation at x60 magnification. CGRP-IR, TH-IR and
VAChT-IR were assessed by measuring the density of
immunoreactivity per area (1 mm2 at × 20 magnifica-
tion). Image J software (National Institute of Health,
Bethesda, MD, USA) was employed to convert images
from RGB to greyscale 8 bit then to binary; particles
were then analysed to obtain the percentage area of immu-
noreactivity [57]. Gross morphological damage in haema-
toxylin and eosin-stained colon sections was visualised
using an Olympus BX53 microscope (Olympus Imaging,
Melbourne, Australia) and images were captured with
CellSenseTM software. Cellular imaging in vitro was per-
formed on an Olympus IX81 inverted microscope (Olym-
pus Imaging) using the same software.
MSC migration assay
The distal colon was collected and high purity myenteric
plexuses were isolated as described by Grundmann et al.
[58]. Tissues were trypsinised for 10 min before cells
were seeded into 24 well plates pre-coated with poly-L-
lysine and laminin containing media. Myenteric plexuses
were cultured for seven days with the media changed
every second day. Medium containing lipopolysaccharide
(LPS) (20 ng/mL; Sigma-Aldrich) was added to cultures
for eight h to stimulate inflammatory conditions prior to
the migration assay. The media conditioned by cells of
the myenteric plexus were collected, pooled together
and filtered through 0.2 μm pore filter to serve as a
chemoattractant in the bottom well of a Boyden cham-
ber. Controls contained unconditioned media without
FBS, with equivalent FBS, or FBS with added LPS
(20 ng/mL). Top wells of the Boyden chamber (pore size
8 μm, Corning Life Sciences, Tewksbury MA, USA)
were loaded with 2x105 BM-MSCs or AT-MSCs. After
72 h in culture, chambers were washed in PBS and cells
in the bottom wells were collected by trypsinisation and
counted by haemocytometry.
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Fig. 1 (See legend on next page.)
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Statistical analysis
Data analysis was performed using GraphPad Prism v6
(GraphPad Software, Inc., San Diego, CA, USA). Data
were analysed using Student’s t-test (two-tailed) and one-
way or two-way analysis of variance (ANOVA) for mul-
tiple group comparisons followed by Tukey’s and Sidak’s
post hoc test. For all analysis p < 0.05 was considered sig-
nificant. All data are presented as mean ± standard error
of the mean (SEM).
Results
In vitro validation and characterisation of BM-MSCs and
AT-MSCs
All experiments were conducted using MSCs cultured
until the fourth passage. Flow cytometry was used to val-
idate the immunophenotype of MSCs. Cell surface ex-
pression of positive MSC markers CD29, CD44, CD73
and CD90 was observed in BM-MSCs (98.5 %, 98.8 %,
98.0 %, and 98.9 %, respectively) and AT-MSCs (99.9 %,
99.8 %, 99.9 %, and 99.6 % respectively) (Fig. 1a). BM-
MSCs demonstrated negligible expression of non-MSC
markers CD34 (2.5 %) and CD45 (3.6 %). In AT-MSCs,
the expression of CD34 was low (10.3 %) while CD45
was negligible (1.6 %). Thus, the immunophenotype of
BM-MSCs and AT-MSCs was in compliance with MSC
definition [2].
MSCs adhered to plastic and proliferated to form
monolayer cultures (Fig. 1b-b′). In addition, BM-MSCs
appeared more sparsely distributed than AT-MSCs. The
multipotent potential of MSCs was assessed by exposing
cells to adipogenic and osteogenic differentiation media.
MSCs stained positive with Oil Red O indicative of suc-
cessful induction to adipocytes with lipid filled vacuoles
(Fig. 1c-d′). Confirmation of differentiation to osteo-
genic lineage was revealed by Alizarin red S staining of
calcium deposition (Fig. 1e-f′). Both BM-MSCs and AT-
MSCs exhibited multipotency and, therefore, were con-
sidered bona fide MSCs.
A CFU-f assay was performed to compare the clono-
genicity between BM-MSCs and AT-MSCs. The per-
centage of MSCs capable of developing into colonies
was greater in AT-MSC cultures (39.0 ± 0.6 %) com-
pared to those of BM-MSCs (14.3 ± 3.0 %, p < 0.01)
after two weeks (Fig. 2a-a′, b, n = 3 independent cul-
tures/group). Subpopulations of MSCs were quantified
by the morphological properties of their cell bodies in
vitro (Fig. 2c-d′). Two prominent morphological types
were exhibited in MSC cultures consisting of cells
with long thin ‘spindle’ shapes (Fig. 2c, d) and ‘flat’
cells with irregular processes (Fig. 2c′, d′). Cell popu-
lations with a ‘spindle’ morphology were more readily
exhibited by AT-MSCs (86.7 ± 6.1 %) than BM-MSCs
(58.3 ± 6.0 %, p < 0.01, n = 6 independent cultures/
group, Fig. 2e). In the contrary, a higher population of
cells with a ‘flat’ morphology was observed in BM-
MSCs (41.7 ± 6.0 %) in comparison to AT-MSCs (13.3
± 6.1 %, p < 0.01). The growth kinetics of MSCs were
quantified over 14 days in culture and an assessment
was made on the population doubling rate (Fig. 2f ).
No difference in the PDL was observed between BM-
MSCs (0.4 ± 0.1) and AT-MSCs (0.4 ± 0.5) after three
days (n = 3 independent cultures/group/time point).
Higher PDL was observed in AT-MSC compared to BM-
MSC cultures at day 7 (5.6 ± 0.1 vs 2.5 ± 0.3, p < 0.0001)
continuing to day 14 (8.4 ± 0.2 vs 6.2 ± 0.2, p < 0.001).
Thus, the in vitro AT-MSC phenotype exhibited charac-
teristics associated with superior cellular expansion.
BM-MSCs and AT-MSCs comparably ameliorate
histological damage and weight loss associated with
TNBS-induced colitis
Gross morphological damage was assessed in haema-
toxylin and eosin-stained cross sections of the colon.
No damage was observed in sham-treated guinea-pigs
(histological score = 0, Fig. 3a-a′). At 24 and 72 h
following the induction of TNBS-induced colitis,
changes to the colonic architecture were observed
including flattening of the mucosa, haemorrhagic
sites, loss of goblet cells and altered presentation of
the circular muscle layer (histological score = 2–3)
(Fig. 3b-b′). These changes were attenuated in both
BM-MSC- and AT-MSC-treated animals at 24 h and
72 h (histological score = 0–1, Fig. 3c-c′, d-d′).
The body weight of guinea-pigs was recorded before
and after treatment at 24, 48 and 72 h (Fig. 3e, Table 1,
n = 4 animals/group/time point). No differences in
weight were observed between treatment groups after
24 h. By 48 and 72 h, the body weight of the TNBS
group was lower compared to the sham group (both p
< 0.001). The reduction in body weight was ameliorated
(See figure on previous page.)
Fig. 1 Phenotypic and functional validation of BM-MSCs and AT-MSCs. a BM-MSCs and AT-MSCs analysed for cell surface antigen expression of
known positive (CD29, CD44, CD73, and CD90) and negative (CD34 and CD45) MSC markers. Red closed histograms represent MSCs labelled with
antibodies against the surface antigen indicated on the right hand side of each row. Blue open histograms show isotype controls. BM-MSCs b and
AT-MSCs b′ adhered to plastic with a perceptible appearance typical of MSCs in culture. Scale bar = 200 μm. BM-MSCs and AT-MSCs cultured without
c-d and with c′-d′ adipogenesis differentiation medium for 14 days and stained with Oil red O. Scale bar = 50 μm. BM-MSCs and AT-MSCs cultured
without e-f and with e′-f′ osteogenesis differentiation medium for 21 days and stained with Alizarin red S. Scale bar = 200 μm. BM-MSCs bone marrow-
derived mesenchymal stem cells, AT-BMCs adipose tissue-derived mesenchymal stem cells
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Fig. 2 (See legend on next page.)
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(See figure on previous page.)
Fig. 2 In vitro clonogenicity, morphology, and growth kinetics of MSCs. Clonogenicity of BM-MSCs a and AT-MSCs a′ determined by a colony
forming unit-fibroblast (CFU-f) assay (n = 3 independent cultures/group). b CFU-f counts quantified as a percentage of the total viable cells
seeded. c-d′) Morphological subpopulations exhibited by BM-MSCs c-c′) and AT-MSCs d-d′ in culture. MSC morphology defined according to the
presence of long thin spindles (‘spindle’: c-d or flat cells with atypical processes (‘flat’: c′-d′) (scale bar = 50 μm). e Quantitative analysis of MSC
morphological types. Data expressed as a percentage of the total cell number in each population (n = 6 independent cultures/group). f) The
population doubling level (PDL) of proliferating MSCs recorded at 3, 7 and 14 days after seeding (n = 3 independent cultures/group/time point).
**p < 0.01, ***p < 0.001, ****p < 0.0001. MSCs mesenchymal stem cells, BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose
tissue-derived mesenchymal stem cells
Fig. 3 Effects of MSC treatment on histological changes and body weight in colitis. Colonic structure assessed via haematoxylin and eosin staining of
cross sections from tissues collected at 24 h a-d and 72 h a′-d′ post TNBS administration. Scale bar = 50 μm. e Body weight recorded at 24, 48 and
72 h after TNBS administration and expressed as the change from baseline measurements. *p < 0.05, **p < 0.01, ***p < 0.001, n = 4 animals/group/time
point. MSC mesenchymal stem cell, TNBS 2,4,6-trinitrobenzene-sulfonate acid
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by both BM-MSC (48 h, p < 0.05 and 72 h, p < 0.01) and
AT-MSC treatments (48 h and 72 h p < 0.05). There-
fore, BM-MSCs and AT-MSCs were equally effective in
attenuating colitis-induced weight loss.
BM-MSCs are more efficient than AT-MSCs in attenuating
leukocyte infiltration to the level of the myenteric ganglia
The number of leukocytes in proximity to the myenteric
plexus were quantified in LMMP preparations of the
guinea-pig colon (Fig. 4a-d′, n = 4 animals/group/time
point). Elevated leukocyte counts (cells/area) were ob-
served in TNBS groups at 24 h (104.8 ± 5.0) and 72 h
(71.8 ± 3.2) compared to shams (24 h: 19.8 ± 1.0 and
72 h: 19.8 ± 1.6, both p < 0.001; Fig. 4e). At 24 h, ele-
vated leukocyte levels were attenuated by BM-MSC
(40.0 ± 3.3, p < 0.01) and AT-MSC (50.5 ± 9.9, p < 0.05)
treatments. However, the number of leukocytes was still
Table 1 Effects of mesenchymal stem cells derived from bone
marrow and adipose tissue on body weight (%) in TNBS-induced
colitis
Sham TNBS TNBS + BM-MSC TNBS + AT-MSC
24 h 102.8 ± 1.0 99.1 ± 1.5 101.1 ± 0.7 101.8 ± 1.9
48 h 107.5 ± 0.9 98.8 ± 2.1 ††† 104.5 ± 1.9 * 105.0 ± 2.0 *
72 h 109.4 ± 0.8 100.3 ± 0.9 ††† 106.9 ± 1.3 ** 105.4 ± 2.4 *
TNBS, 2,4,6-trinitrobenzene sulfonic acid, BM-MSC bone marrow-derived MSC,
AT-MSC adipose tissue derived MSC
*p < 0.05, **p < 0.01, significantly different to TNBS; †††p < 0.001, significantly
different to sham
Fig. 4 Effects of MSCs on leukocyte infiltration to the myenteric plexus. a-d′ CD45-IR leukocytes (green) visualised on the level of myenteric neurons
labelled with anti-PGP9.5 (red) by confocal microscopy in LMMP wholemounts prepared from colon collected at 24 a-d and 72 h a′-d′ post treatment.
Scale bar = 50 μm. e CD45-IR leukocytes quantified in a 2 mm2 area of the myenteric plexus in the colon. *p < 0.05, **p < 0.01, ***p < 0.001, n = 4
animals/group/time point. MSCs mesenchymal stem cells, LMMP longitudinal muscle and myenteric plexus
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elevated in AT-MSC-treated animals in comparison to
sham (p < 0.05). By 72 h, TNBS-induced leukocyte infil-
tration was mitigated by BM-MSC (24.0 ± 1.7, p < 0.01)
and AT-MSC (25.0 ± 3.2, p < 0.01) treatments to levels
comparable to shams. These results demonstrate that
both MSC types can attenuate plexitis; however BM-
MSCs appear to act faster.
BM-MSCs and AT-MSCs have comparable efficacy for
attenuating inflammation-induced enteric neuropathy
The pan neuronal marker HuC/D was used to assess
the neuroprotective efficacy of MSCs in wholemount
LMMP preparations (Fig. 5a-d′, n = 4 animals/group/time
point). In comparison to sham, the administration of
TNBS resulted in neuronal loss at 24 h (p < 0.0001) which
persisted at 72 h (p < 0.001, Fig. 5e, Table 2). The loss of
neurons was ameliorated at both time points by BM-
MSC (24 h: p < 0.0001 and 72 h: p < 0.01) and AT-MSC
treatments (24 h: p < 0.001 and 72 h: p < 0.01). How-
ever, AT-MSC treatment was less effective and differ-
ences to the sham groups were observed at 24 and 72 h
(both p < 0.05, Fig. 5e).
Inhibitory and excitatory neurons, defined by
nNOS-IR and ChAT-IR respectively, were quantified
within the myenteric ganglia (Figs. 6a-d′ and 7a-d′,
Table 2, n = 4 animals/group/time point). Increased
numbers (both p < 0.001) and proportions (both p <
0.0001) of nNOS-IR neurons were observed in my-
enteric ganglia from TNBS groups at 24 and 72 h
compared to sham (Fig. 6e-f, Table 2). BM-MSC and
AT-MSC treatments attenuated these changes in the
total number (BM-MSC: 24 h and 72 h, p < 0.01 and
AT-MSC: 24 h, p < 0.01 and 72 h, p < 0.05) and pro-
portion of nNOS-IR neurons at both time points
(BM-MSC: 24 h and 72 h, p < 0.0001; AT-MSCs:
24 h, p < 0.0001 and 72 h, p < 0.001). The total
Fig. 5 Effects of BM-MSCs and AT-MSCs on the total number of myenteric neurons. a-d′ Neuronal cell bodies in the myenteric plexus were
labelled with the pan neuronal marker anti-HuC/D antibody at 24 a-d and 72 h a′-d′ post treatment. Scale bar = 50 μm. e The total number of
neuronal bodies were quantified within a 2 mm2 area of the myenteric plexus. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 4 animals/
group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose tissue-derived mesenchymal stem cells
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numbers of ChAT-IR neurons were decreased at both
24 and 72 h after TNBS administration compared to
sham (p < 0.0001 for both time points) (Fig. 6e,
Table 2). The loss of ChAT-IR neurons was attenu-
ated at 24 and 72 h by treatments with BM-MSCs
(p < 0.0001) and AT-MSCs (p < 0.001 for both time
points). However, the number of ChAT-IR neurons
were still less than sham after AT-MSC treatment at
24 h (p < 0.05). Quantification of the proportion of
ChAT-IR neurons revealed no differences between
groups (Fig. 6f, Table 2). Thus, although both BM-MSCs
and AT-MSCs were effective in attenuating neuronal loss
and changes in nNOS and ChAT immunoreactivity, AT-
MSCs were less efficacious compared to BM-MSCs in
treating neuropathy.
BM-MSCs and AT-MSCs mitigate the loss of nerve fibres
in the inflamed colon
Immunoreactivity for CGRP (sensory), TH (sympathetic)
and VAChT (cholinergic) was assessed within the my-
enteric plexus in LMMP preparations (Figs. 8a-d′, 9a-d′
and 10a-d′, Table 3). At 24 and 72 h, TNBS adminis-
tered groups exhibited decreased density of CGRP im-
munoreactivity (Fig. 8e, p < 0.0001 for both time
points) compared to shams. At these time points, BM-
MSC and AT-MSC treatments attenuated the loss of
CGRP immunoreactivity (BM-MSC: p < 0.001 for both
time points; AT-MSC: 24 h, p < 0.05 and 72 h p <
0.001). However, the loss of CGRP-IR was not pre-
vented to the levels of sham groups by BM-MSCs (p <
0.01 for both time points) and AT-MSCs (24 h, p <
0.001 and 72 h, p < 0.01) treatments. Similar loss in
density was observed after TNBS administration in
TH-IR (Fig. 9e, both p < 0.01) and VAChT-IR nerve fi-
bres (Fig. 10e, both p < 0.0001) compared to shams.
BM-MSC and AT-MSC treatments ameliorated the
loss of TH-IR (BM-MSC: 24 h, p < 0.01 and 72 h, p <
0.05; AT-MSC: p < 0.01 for both time points) and
VAChT-IR (all p < 0.0001) nerve fibres. BM-MSCs and
AT-MSCs were equally efficacious in attenuating the
loss of nerve fibre immunoreactivity.
BM-MSCs and AT-MSCs migrate to the myenteric plexus
BM-MSCs and AT-MSCs were detected in cross-
sections of the colon at 24 h and 72 h as defined by
HLA-IR (Fig. 11a-d′′). Predominantly, MSCs were ob-
served within the mucosa and to a lesser extent in the
submucosa. A relatively low number of HLA-IR cells
was observed in the muscle layers. High magnification
confocal images (x100) confirmed the presence of HLA-
IR cells at the level of the myenteric ganglia in both BM-
MSC (Fig. 11e-e′) and AT-MSC (Fig. 11f-f′) treated
groups.
To assess the migration of MSCs to the inflamed my-
enteric plexus, an in vitro migration assay was performed
using LPS stimulated neurons as a chemoattractant
(Fig. 12). BM-MSCs and AT-MSCs had a higher affinity to
migrate to the conditioned medium of LPS-stimulated
myenteric neurons (BM-MSC: 5.6 ± 0.4 × 103; AT-MSC:
4.5 ± 0.2 × 103) compared to control media without FBS
(BM-MSC: 3.3 ± 0.5 × 103; AT-MSC: 2.2 ± 0.2 × 103, p <
0.01 for both) or supplemented with FBS (BM-MSC: 2.9 ±
0.3 × 103, p < 0.001; AT-MSC: 2.6 ± 0.5 × 103, p < 0.05) and
medium containing the same amount of LPS (20 ng/mL)
as the conditioned medium of LPS-stimulated myenteric
neurons (BM-MSC: 2.0 ± 0.2 × 103, p < 0.0001; AT-MSC:
2.3 ± 0.3 × 103, p < 0.01). No differences in migration were
observed between BM-MSCs and AT-MSCs.
Discussion
This is the first study comparing the neuroprotective
efficacy of AT-MSCs and BM-MSCs in a model of col-
itis. In vitro, AT-MSCs possessed a superior phenotype
for cellular expansion. Both AT-MSCs and BM-MSCs
demonstrated therapeutic efficacy in the amelioration of
weight loss, histopathology, leukocyte infiltration to the
myenteric plexus, neuronal loss, altered neurochemical
expression, and damage to nerve fibres. However, AT-
MSCs appeared less effective in the attenuation of plexitis,
neuropathy, and reduction in ChAT immunoreactivity.
Table 2 Effects of mesenchymal stem cells derived from bone
marrow and adipose tissue on myenteric neurons in TNBS-induced
colitis
Sham TNBS TNBS + BM-MSC TNBS + AT-MSC
Total number of myenteric neurons/2 mm2
24 h 263.8 ± 3.5 202.5 ± 8.4 †††† 258.8 ± 2.9 **** 242.8 ± 6.2 *** †
72 h 262.0 ± 5.1 204.0 ± 5.4 ††† 258.8 ± 7.6 ** 240.5 ± 10.0 ** †
Total number of nNOS-IR neurons/2 mm2
24 h 52.3 ± 1.8 70.0 ± 4.9 ††† 55.0 ± 3.2 ** 53.5 ± 2.6 **
72 h 52.5 ± 1.0 70.5 ± 3.2 ††† 55.3 ± 2.7 ** 57.3 ± 1.7 *
Proportion of nNOS-IR neurons/2 mm2 (%)
24 h 19.9 ± 0.9 34.8 ± 2.8 †††† 21.3 ± 1.2 **** 22.1 ± 1.1 ****
72 h 20.2 ± 0.3 34.6 ± 1.8 †††† 21.4 ± 1.3 **** 23.9 ± 0.7 ***
Total number of ChAT-IR neurons/2 mm2
24 h 163.5 ± 2.1 111.3 ± 5.7 †††† 148.3 ± 4.6 **** 144.5 ± 4.9 *** †
72 h 157.8 ± 6.3 112.3 ± 1.7 †††† 147.5 ± 7.3 **** 145.3 ± 3.4 ***
Proportion of ChAT-IR neurons/2 mm2 (%)
24 h 62.0 ± 1.4 55.1 ± 2.9 57.3 ± 1.6 59.5 ± 0.9
72 h 59.1 ± 0.9 55.2 ± 2.3 57.1 ± 3.0 60.7 ± 2.5
TNBS 2,4,6-trinitrobenzene sulfonic acid, BM-MSC bone marrow-derived MSC,
AT-MSC adipose tissue-derived MSC, MSC mesenchymal stem cell, nNOS neuronal
nitric oxide synthase, ChAT choline acetyltransferase, IR immunoreactive
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly different to TNBS;
†p < 0.05, †††p < 0.001, ††††p < 0.0001, significantly different to sham
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MSCs used in this study were validated according to
the guidelines of the International Society for Cellular
Therapy [2]. BM-MSCs and AT-MSCs displayed a typ-
ical surface marker phenotype including positive expres-
sion of CD29, CD44, CD73, and CD90 in addition to
negligible expression of CD45. AT-MSCs exhibited low
positive expression of CD34; however, it is now accepted
that CD34+ MSCs are a common subpopulation residing
in the adipose tissue [59]. MSCs from both sources dem-
onstrated multipotency by differentiation into adipocytes
and osteocytes when cultured in media supplemented
with appropriate differentiation factors. Both cell types
were plastic adherent and proliferated to form colonies,
a definitive characteristic of MSCs.
In vitro expansion of MSC cultures is fundamental to
obtain appropriate numbers for therapeutic application.
Our results show that after an initial ~3-day lag period,
AT-MSCs proliferate at a higher rate than BM-MSCs
yielding greater quantities of cells. Other studies have
shown similar differences in proliferation exhibited by
BM-MSCs and AT-MSCs [60–62]. The ability of MSCs
to form colonies is reflective of their expansive capacity
[63]. The CFU-f assay is regarded as the gold standard
for identifying clonogenic MSCs [64]. Both MSC types
were capable of developing colony forming units. How-
ever, AT-MSCs produced more than twice the number
of colony forming units compared to BM-MSCs. Simi-
lar results have been reported in multiple human MSC
lines [63].
The heterogeneous in vitro characteristics of BM-
MSCs and AT-MSCs were further elucidated by defining
morphological subpopulations. AT-MSC cultures were
dominated by cells with ‘spindle’ morphology. Inversely,
the proportion of ‘flat’ MSCs was greater in BM-MSC
cultures. In agreement with these results, rat AT-MSCs
have also been observed to contain higher populations
of ‘spindle’ shaped cells with higher proliferative capacity
[65]. Evidence of a direct relationship between MSC
Fig. 6 Effects of BM-MSCs and AT-MSCs on nitrergic myenteric neurons. a-d′ Nitrergic (nNOS-IR) neurons were visualised in the myenteric plexus
at 24 a-d and 72 h a′-d′. Scale bar = 50 μm. The total number of nNOS-IR neurons e and the proportion of nNOS-IR neurons to the total number
of HuC/D-IR neurons f were quantified within a 2 mm2 area of the myenteric plexus in the guinea-pig colon. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001, n = 4 animals/group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose tissue-derived
mesenchymal stem cells
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morphology and expansive characteristics arise from the
parallels of decreasing proliferation and clonogenicity
[66, 67] and increasing populations of ‘flat’ MSCs [68]
over subsequent passaging. Nonetheless, differences in
proliferation and clonogenicity between BM-MSCs and
AT-MSCs are observed consistently at equivalent pas-
sages [60–63]. In our study, colony forming units were
predominantly populated by ‘spindle’ MSCs suggesting a
link between morphology and clonogenicity. It should
be noted that ‘flat’ MSCs were also observed to be clo-
nogenic; however, these colonies were rarely detected by
the CFU-f assay due to their inferior proliferative nature.
Nonetheless, these data collectively suggest that mor-
phological subpopulations may be indicative of expan-
sion potential, which could be useful information when
propagating MSC therapies in the clinic. Due to the
great number of MSCs required for human therapy, the
in vitro phenotype is a crucial consideration to
determine the favourable source of MSC treatment in
the clinic. AT-MSCs were shown to exhibit superior in
vitro properties. However, the in vivo therapeutic effi-
cacy of MSCs from different sources also requires
attention.
In our study, the efficacy of BM-MSCs and AT-MSCs
was assessed in an in vivo model of intestinal inflamma-
tion induced by administering TNBS which initiated an
immune response to hapten modified autologous proteins
[69]. Lack of weight gain is commonly observed in this
model and is reflective of the inflammatory state [70, 71].
This effect was comparably attenuated in guinea-pigs
treated with BM-MSCs and AT-MSCs. The histopatho-
logical severity of experimental colitis has been
evaluated to determine the effectiveness of MSC treat-
ments [26, 30, 72, 73]. In our study, both MSC treat-
ments similarly prevented disruption to the epithelial
lining, inflammatory infiltrate and changes to the
Fig. 7 Effects of BM-MSCs and AT-MSCs on cholinergic myenteric neurons. a-d′ Cholinergic (ChAT-IR) neurons in the myenteric plexus at 24 a-d
and 72 h a′-d′. Scale bar = 50 μm. The total number of ChAT-IR neurons e and the proportion of ChAT-IR neurons to the total number of HuC/
D-IR neurons f were quantified within a 2 mm2 area of the myenteric plexus in the guinea-pig colon. *p < 0.05, ***p < 0.001, ****p < 0.0001,
n = 4 animals/group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose tissue-derived mesenchymal stem
cells, ChAT choline acetyltransferase, IR immunoreactive
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colonic architecture. Previous comparisons of allogen-
eic rat MSCs from these tissue sources in experimental
colitis are in agreement with these observations [31].
While MSCs from both sources were seemingly equally
beneficial in attenuating the manifestations of TNBS-
induced colitis, we further investigated their therapeutic
efficacy for the treatment of enteric neuropathy associ-
ated with intestinal inflammation.
The increased number of leukocytes in proximity to
myenteric ganglia upon administration of TNBS, indica-
tive of plexitis, was prevented by both MSC treatments.
However, leukocyte numbers were still elevated after
AT-MSC treatment compared to shams at early stages of
inflammation which suggests that AT-MSCs exert their
immunomodulatory effects more slowly than BM-MSCs.
Previous studies in various pathologies appear to be in
agreement that BM-MSCs are superior to AT-MSCs in
preventing leukocyte infiltration and inflammation
[21–24]. The infiltration of leukocytes to the myenteric
plexus in the resected bowel of Crohn’s disease pa-
tients is predictive of inflammatory relapse requiring
repeated surgery [45, 46]. Enteric neurons express receptors
for inflammatory mediators, activation of which causes sub-
stantial excitation in enteric neurons [74]. Inflammation-
induced neuronal death and axonal damage leads to
changes in neurally-controlled intestinal functions [75, 76].
Neuronal loss was observed in animals administered
with TNBS in our study consistent with previous reports
[40–42]. Both BM-MSCs and AT-MSCs attenuated neur-
onal loss in animals with colitis, however BM-MSCs were
more effective compared to AT-MSCs. In the myenteric
plexus, the two major subpopulations of excitatory and
inhibitory muscle motor and interneurons, ChAT-IR
(cholinergic) and nNOS-IR (nitrergic), were further
Fig. 8 Effects of BM-MSCs and AT-MSCs on CGRP-IR nerve fibres in the myenteric plexus. a-d′ CGRP-IR in the myenteric plexus at 24 h a-d and
72 h a′-d′. Scale bar = 100 μm. e Area percentage quantification of CGRP-IR within a 1 mm2 area of the myenteric plexus in the guinea-pig colon.
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 3 animals/group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs
adipose tissue-derived mesenchymal stem cells, CGRP calcitonin gene-related peptide, IR immunoreactive
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investigated [77]. Changes in the neurochemical coding of
these neurons are associated with altered coordination of
muscular contractions and dysmotility in humans and ani-
mals [78–80]. Intestinal dysmotility is a symptom of IBD;
however, it may also contribute to disease progression
through dysfunctional propulsive clearance of entero-
toxins that promote additional inflammatory bouts [81].
Administration of TNBS resulted in decreased numbers of
cholinergic neurons. Cholinergic neuronal loss was atten-
uated by both BM-MSCs and AT-MSCs. Similar to total
neuronal counts, AT-MSCs were less effective at attenuat-
ing cholinergic neuronal loss at 24 h. The unchanged pro-
portion of cholinergic neurons may be attributed to the
parallel loss of total myenteric neurons [41]. Intestinal in-
flammation induced by TNBS increased the total numbers
and proportions of nNOS-IR nitrergic neurons. Similar
changes to the neurochemical coding of enteric neurons
have been observed in experimental models of colitis [80]
and in Crohn’s disease patients [47, 82]. Furthermore,
neurons in the central nervous system reportedly increase
in nNOS expression in response to inflammatory stimuli
[83, 84]. MSCs from both sources similarly attenuated
neurochemical alterations in nitrergic neurons. Excessive
nitric oxide has been linked to neuropathy in enteric neu-
rons upon intestinal inflammation [85] and likewise with
peripheral motor neurons [86, 87]. Thus, attenuating in-
creases in nNOS could be partially responsible for the
therapeutic action of MSCs in neuropathy.
The loss of nerve fibres in the myenteric plexus was
prominent after TNBS administration in our study. TH-
IR nerve fibres represent extrinsic noradrenergic sympa-
thetic fibres in the myenteric plexus projecting to the
ganglia, mucosa, and blood vessels which regulate motil-
ity and vasomotor function [77, 88, 89]. Sympathetic
Fig. 9 Effects of BM-MSCs and AT-MSCs on TH-IR nerve fibres in the myenteric plexus. a-d′ TH-IR nerve fibres in the myenteric plexus at 24 h a-d
and 72 h a′-d′. Scale bar = 100 μm. e Area percentage quantification of TH-IR nerve fibres within a 1 mm2 area of the myenteric plexus in the
guinea-pig colon. *p < 0.05, **p < 0.01, n = 3 animals/group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose
tissue-derived mesenchymal stem cells, TH tyrosine hydroxylase, IR immunoreactive
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neurotransmitters can have pro- and anti-inflammatory
effects depending on concentration [90]. Damage to
sympathetic nerve fibres have been reported in Crohn’s
disease patients [91]. In acute experimental colitis, sym-
pathectomy improves outcomes but conversely has adverse
effects in chronic models [91]. This suggests that sympa-
thetic innervation may possess beneficial anti-inflammatory
properties in chronic stages of intestinal inflammation. Im-
munoreactivity for VAChT identifies cholinergic fibres from
a broad range of neurons including extrinsic vagal, intrinsic
excitatory muscle motor neurons, ascending and descend-
ing interneurons, primary afferent neurons and intestinofu-
gal afferent neurons [92]. The loss of innervation from
these fibres may have repercussions in immunomodulation.
Acetylcholine has been identified as a potent immuno-
modulator. The inflammatory reflex mediated through
the efferent and afferent arms of cholinergic vagal fibres
innervating the mucosa is suggested to prevent the re-
lease of pro-inflammatory mediators from macrophages
Fig. 10 Effects of BM-MSCs and AT-MSCs on VAChT-IR nerve fibres in the myenteric plexus. a-d′ VAChT-IR nerve fibres in the myenteric plexus at
24 h a-d and 72 h a′-d′. Scale bar = 100 μm. e Area percentage quantification of VAChT-IR nerve fibres within a 1 mm2 area of the myenteric
plexus in the guinea-pig colon. ****p < 0.0001, n = 3 animals/group/time point. BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs
adipose tissue-derived mesenchymal stem cells, VAChT vesicular acetylcholine transporter, IR immunoreactive
Table 3 Effects of mesenchymal stem cells derived from bone
marrow and adipose tissue on nerve fibre density in TNBS-induced
colitis
Sham TNBS TNBS + BM-MSC TNBS + AT-MSC
Level of CGRP immunoreactivity/1 mm2 (%)
24 h 12.0 ± 0.1 6.3 ± 0.6 †††† 9.5 ± 0.5 *** †† 8.5 ± 0.4 * †††
72 h 12.2 ± 0.4 6.1 ± 0.4 †††† 9.6 ± 0.7 *** †† 9.4 ± 0.3 *** ††
Density of TH-IR nerve fibres/1 mm2 (%)
24 h 17.2 ± 0.8 11.6 ± 0.4 †† 17.4 ± 0.1 ** 16.8 ± 0.9 **
72 h 17.4 ± 1.1 12.6 ± 0.4 †† 17.0 ± 1.3 * 17.5 ± 1.2 **
Density of VAChT-IR nerve fibres/1 mm2 (%)
24 h 19.9 ± 0.9 11.6 ± 0.8 †††† 20.3 ± 0.5 **** 19.9 ± 0.2 ****
72 h 20.5 ± 1.1 12.9 ± 0.4 †††† 19.6 ± 0.7 **** 20.0 ± 0.6 ****
TNBS 2,4,6-trinitrobenzene sulfonic acid, BM-MSC bone marrow derived
mesenchymal stem cells, AT-MSC adipose tissue derived mesenchymal stem
cells, CGRP calcitonin gene-related peptide, TH tyrosine hydroxylase,
VAChT vesicular acetylcholine transporter, IR immunoreactive
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, significantly different to TNBS;
††p < 0.01, †††p < 0.001, ††††p < 0.0001, significantly different to sham
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via the α7 nicotinic cholinergic receptor [93, 94]. In our
study, the loss of cholinergic fibres coincided with the loss
of cholinergic neurons in the myenteric plexus, suggesting
that most damaged fibres were of intrinsic origin. Both
BM-MSC and AT-MSC treatments attenuated the loss of
cholinergic and sympathetic nerve fibres to levels compar-
able with controls.
In the myenteric plexus, sensory extrinsic afferent fibres,
as well as intrinsic afferent neurons and fibres, are immu-
noreactive for CGRP. Reduced CGRP immunoreactivity
was observed in the myenteric plexus from inflamed ani-
mals. In ulcerative colitis, lack of CGRP expression corre-
lates with disease activity scores and may be a useful
marker of disease progression [95]. Furthermore, abroga-
tion of CGRP signalling via neutralising antibodies or as-
sociated receptor antagonist promotes inflammation in
experimental colitis [96]. Together this suggests that sen-
sory nerve fibres may play an anti-inflammatory role. In
our study, BM-MSCs and AT-MSCs attenuated the loss of
CGRP immunoreactivity, although levels remained lower
compared to shams. This may be reflective of chemore-
pulsive mechanisms inhibiting sensory fibre projections
[97], which might be an endogenous mechanism to pre-
vent pain or hypersensitivity; however, this needs to be
elucidated.
The mechanisms responsible for MSC-mediated neu-
roprotection in the ENS are yet to be investigated. In
this study, BM-MSCs were more efficacious at amelior-
ating neuropathy and plexitis. This correlation may sug-
gest immunomodulatory effects are responsible for the
neuroprotective properties exerted by MSCs. However,
this does not explain the equality of BM-MSCs and AT-
MSCs in attenuating inflammation-induced damage to
nerve fibres and changes to neurochemical coding ob-
served in our study. Both BM-MSCs and AT-MSCs
release neurotrophic factors including nerve growth fac-
tor, brain derived neurotrophic factor, neurotrophin-3
and glial derived neurotrophic factor [65]. These factors
Fig. 11 In vivo migration of BM-MSCs and AT-MSCs. a-d′′ Cross-sections of the guinea-pig colon after treatment with BM-MSCs a-b and AT-MSCs
c-d labelled with anti-HLA a-d to detect human MSCs and anti-α-actin to visualise smooth muscle a′-d′. Scale bar = 50 μm. e′-f′ High magnification
confocal images (x100) of myenteric ganglia from BM-MSC e-e′ and AT-MSC-treated guinea-pigs f-f′. Scale bar = 10 μm. BM-MSCs bone marrow-derived
mesenchymal stem cells, AT-MSCs adipose tissue-derived mesenchymal stem cells, HLA human leukocyte antigen
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have all been linked to neuroprotective effects [98–100].
Thus, the neuroprotective action of MSCs may occur via
immunomodulation, directly by paracrine secretion of
neurotrophic factors or synergistically through both.
Furthermore, the neuroprotective efficacy of MSCs
could be associated with their ability to migrate and
engraft in proximity to enteric neurons.
In our study, MSCs administered by enema migrated
transmurally from the mucosa to the myenteric ganglia,
although most MSCs were observed in the mucosa. The
low number of MSCs migrating to the muscle layers,
relative to the mucosa, might be due to the short length
of experiments in this study as greater numbers of MSCs
migrating to the muscle layers have been observed at
late stages of experimental colitis [32]. To assess the
chemotactic properties of MSCs, an in vitro assay was
designed to determine MSC migration toward secreted
factors released by cultured cells of the myenteric plexus
under simulated inflammatory conditions. Both AT-
MSCs and BM-MSCs migrated towards the milieu of
LPS-damaged neurons within a 72 h period. In agree-
ment with our in vivo data, the proportion of MSCs with
chemotactic affinity was low and differences were not
observed between tissue sources. In other neuroinflam-
matory models, such as experimental autoimmune en-
cephalomyelitis, AT-MSCs were more therapeutic than
BM-MSCs due to their enhanced migratory capabilities
[25]. In the rat model of intestinal inflammation, it has
been reported that intraperitoneally injected AT-MSCs
migrated from the peritoneum through to the epithelial
layer, whereas BM-MSCs only localized to the periton-
eum surface, muscular layers, and submucosa by 72 h
[31]. The direction of migration suggests a high chemo-
tactic affinity to the mucosal, or possibly submucosal,
layers where tissue damage is most prominent. The dis-
similarities between BM-MSC and AT-MSC migration
in these studies could be explained by their differential
expression of chemokine receptors [101]. In addition,
the morphological analysis performed in our study may
suggest that BM-MSCs, containing greater proportions
of large ‘flat’ cells, may be limited in migration due to
their physical size. Nonetheless, MSC migration did not
appear to greatly influence the therapeutic outcomes of
this study or that conducted by Castelo-Branco et al.
[31]. The low affinity of MSC migration to the my-
enteric plexus in our study suggest that either low
numbers of MSCs are required to exert therapeutic
effects on myenteric neurons, or, the proximity of
MSCs is irrelevant to their neuroprotective mechanism.
Investigations into paracrine secretion may explain the
differences observed in this study between BM-MSCs
and AT-MSCs.
Fig. 12 In vitro migration of BM-MSCs and AT-MSCs. Quantification of MSC migration towards the conditioned media of cultured myenteric plexus (MP)
cells pre-stimulated with LPS in a modified Boyden chamber assay. **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 4 independent cultures/group.
BM-MSCs bone marrow-derived mesenchymal stem cells, AT-MSCs adipose tissue-derived mesenchymal stem cells, LPS lipopolysaccharide
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Conclusions
Optimisation of MSC therapies is of critical importance
for their clinical application. Identifying the ideal tissue
source of MSCs for the treatment of intestinal inflamma-
tion may lead to improved therapeutic outcomes. In vitro,
AT-MSCs were determined to have greater proliferation,
clonogenicity, and ‘spindle’ morphology suggesting that
AT-MSCs are ideal for cellular expansion. In vivo, both
BM-MSCs and AT-MSCs ameliorated weight loss, histo-
pathological changes, plexitis, neuropathy, changes to
neuronal neurochemical coding, and loss of nerve fibres;
however, BM-MSCs appeared to be more effective in the
treatment of neuropathy and plexitis. These differences
could not be explained by migration capacity to the my-
enteric plexus both in vivo and in vitro. Future studies
should determine the role of paracrine secretion in the
neuroprotective efficacy of MSCs in addition to their dir-
ect and indirect interactions with myenteric neurons. The
benefits between the expansiveness of AT-MSCs and the
increased efficacy of BM-MSCs to target neurological
manifestation should be considered when selecting MSCs
to treat intestinal inflammation.
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